title: Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant.
abstract: Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine against severe acute respiratory syndrome coronavirus (SARS). Detailed methods are presented for expression, purification, and release testing of SARS recombinant spike protein antigen, followed by adjuvant formulation and animal testing. The methods herein described for rapid development of a highly protective SARS vaccine are equally suited to rapid development of vaccines against other fatal human coronavirus infections, e.g., the MERS coronavirus.
authors.affiliation: Protein Sciences Corporation Inc, Meriden, CT, USA.
authors.forename: Clifton
authors.initials: C
authors.lastname: McPherson
authors.affiliation: Protein Sciences Corporation Inc, Meriden, CT, USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Chubet
authors.affiliation: Protein Sciences Corporation Inc, Meriden, CT, USA.
authors.forename: Kathy
authors.initials: K
authors.lastname: Holtz
authors.affiliation: Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042, Australia.
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Honda-Okubo
authors.affiliation: Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT, 84322-560, USA.
authors.forename: Dale
authors.initials: D
authors.lastname: Barnard
authors.affiliation: Protein Sciences Corporation Inc, Meriden, CT, USA.
authors.forename: Manon
authors.initials: M
authors.lastname: Cox
authors.affiliation: Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042, Australia. nikolai.petrovsky@flinders.edu.au.|Department of Diabetes and Endocrinology, Flinders University, Adelaide, SA, 5042, Australia. nikolai.petrovsky@flinders.edu.au.
authors.forename: Nikolai
authors.initials: N
authors.lastname: Petrovsky
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D006801:Humans; D007444:Inulin / Q000276:immunology*; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D045169:Severe Acute Respiratory Syndrome / Q000276:immunology; D064370:Spike Glycoprotein, Coronavirus / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D064370:Spike Glycoprotein, Coronavirus; D014765:Viral Vaccines; D007444:Inulin
keywords: Adjuvant; Advax adjuvant; Baculovirus; Coronavirus; Delta inulin; MERS; Manufacture; SARS; Vaccine; cGMP